Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (21)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Park, C.
Right arrow Articles by Kang, W. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Park, C.
Right arrow Articles by Kang, W. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 22, No. 10, 1727-1731, October 2001
© 2001 Oxford University Press

SHORT COMMUNICATION

Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death

Chaehwa Park, Inkyoung Lee and Won Ki Kang,1

Department of Medicine and Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-Dong, Kangnam-Ku, Seoul, Korea

Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, induces growth arrest in a variety of cancer cell lines. Its mechanism of action, however, has not been completely elucidated. E2F-1 is thought to act as an oncogene and a tumour suppressor, with its action probably dependent upon the cellular context. We have shown in this study that transcriptional regulation and proteasomal degradation of E2F-1 are critical regulatory events in lovastatin-induced cell death. Accompanying this is a reduction in the E2F-1-regulated expression of cell cycle genes such as c-myc, cyclin D1, cyclin A and cyclin B1. Cell cycle analysis demonstrated that the accumulation of apoptotic cells was preceded by a progressive decrease in the S-phase cell population in response to lovastatin. Although expression of E2F-1 was reduced in three prostate cancer cell lines—PC-3, LNCaP and DU-145—the p21 and p27 protein levels were not increased in all the cell lines treated, suggesting that increase in p21 and p27 protein expression per se is not responsible for lovastatin-mediated down-regulation of E2F-1. The subsequent apoptotic death of these cells in the presence of lovastatin can be prevented by forced ectopic expression of E2F-1. Taken together, these facts imply that E2F-1 is the target of an HMG-CoA inhibitor and critical cell death mediator in prostate cancer cells.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
S.-H. Tan and M. T Nevalainen
Signal transducer and activator of transcription 5A/B in prostate and breast cancers
Endocr. Relat. Cancer, June 1, 2008; 15(2): 367 - 390.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M.-A. Shibata, Y. Ito, J. Morimoto, and Y. Otsuki
Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism
Carcinogenesis, October 1, 2004; 25(10): 1887 - 1898.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
H. Mo and C. E. Elson
Studies of the Isoprenoid-Mediated Inhibition of Mevalonate Synthesis Applied to Cancer Chemotherapy and Chemoprevention
Experimental Biology and Medicine, July 1, 2004; 229(7): 567 - 585.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. L. Carey, L. M. Sasur, H. Kawakubo, V. Gupta, B. Christian, P. M. Bailey, and S. Maheswaran
Mutually Antagonistic Effects of Androgen and Activin in the Regulation of Prostate Cancer Cell Growth
Mol. Endocrinol., March 1, 2004; 18(3): 696 - 707.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. Kim, R. M. Adam, K. R. Solomon, and M. R. Freeman
Involvement of Cholesterol-Rich Lipid Rafts in Interleukin-6-Induced Neuroendocrine Differentiation of LNCaP Prostate Cancer Cells
Endocrinology, February 1, 2004; 145(2): 613 - 619.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.